SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Bosulif

PFE·PFIZER INC
BEARISH
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market since 2012. Generic competition entered in June 2026.
Why 3/10
Bosulif is an already-approved, marketed drug with no pending PDUFA date, Advisory Committee, or pivotal readout scheduled in the next 12 months. The defining binary event (generic entry) occurred in June 2026. For Pfizer, a $63B+ revenue company, Bosulif's roughly $600M in annual sales is a small contributor, so even complete erosion would not drive a material share-price move. ImpactScore is 3 per the rubric: approved and commercializing with no pending regulatory decision.
Actionable Insight BEARISH

Bosulif has no upcoming FDA decision or pivotal readout. The key event already occurred in June 2026 with the launch of generic bosutinib, which will progressively erode brand revenue. For Pfizer investors, the drug is too small to move the stock meaningfully; the more relevant Pfizer catalysts are its broader pipeline readouts and overall revenue trajectory.

Price Chart

Loading chart...

Executive Summary

Bosulif (bosutinib) is Pfizer's approved oral tyrosine kinase inhibitor for Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), first FDA-approved in September 2012. The drug is a mature, marketed product facing a significant loss of exclusivity event: generic competition launched in June 2026, with Dr. Reddy's launching the 400mg strength (with 180-day exclusivity) and Alembic launching 100mg and 500mg generics. Bosulif is a small product within Pfizer's roughly $63B annual revenue base, with estimated global sales around $611M in 2025. There are no upcoming binary catalysts (PDUFA dates, pivotal readouts) for this drug, and the generic erosion story is already in motion.

How It Works

Bosulif is a targeted oral cancer drug that blocks a specific abnormal protein called BCR-ABL, which drives the growth of leukemia cells in chronic myelogenous leukemia (CML). By inhibiting this protein and related Src-family kinases, it slows or stops the proliferation of cancer cells.

Trial Status

Bosulif was FDA-approved in September 2012 for adult patients with Ph+ CML. It is approved for both newly diagnosed chronic-phase CML and previously treated patients (including those with resistance or intolerance to prior therapy). The drug is commercially marketed and has an established safety/efficacy profile from multiple clinical trials.

The Two-Sided Case

▲ Bull Case4
Bosulif remains a standard-of-care option in Ph+ CML with established physician prescribing and patient familiarity.
The drug has a broad label covering both newly diagnosed and treatment-resistant CML, supporting continued use despite generic competition.
Pfizer's large commercial infrastructure and patient support programs (Pfizer Oncology Together) may help retain some brand-loyal patients and prescribers.
Latest Orange Book patent expiry is August 2034, suggesting some form of protection could persist for certain formulations or indications.
▼ Bear Case5
Generic bosutinib launched in June 2026: Dr. Reddy's launched the 400mg strength with 180-day exclusivity, and Alembic launched 100mg and 500mg generics, directly eroding Bosulif brand revenue.
Bosulif 400mg had approximately $253.8M in US sales for the 12 months ended April 2026, and the 100mg/500mg strengths had $291M for the 12 months ended March 2025, representing a significant revenue base now at risk.
Global Bosulif sales declined from $645M in 2024 to $611M in 2025 (-5.6%) even before generic entry, indicating pre-existing competitive pressure.
The CML treatment market is crowded with multiple tyrosine kinase inhibitors including Novartis's imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna), plus newer entrants.
Bosulif is a very small product within Pfizer's portfolio (under 1% of total revenue), so it receives limited strategic focus or investment from the company.

Upcoming Catalysts

  • No upcoming binary catalysts for Bosulif. The drug is already approved and generic competition has launched.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 11

Hover a chip for the title
1 pfizer.com2 en.wikipedia.org3 drugs.com4 businesswire.com5 business.optum.com6 business-standard.com7 pharmacompass.com8 cliffbio.com9 assyro.com10 sec.gov11 stockanalysis.com